Year: 2018

Genetic Disorders in Clinical Trials

December 20, 2018 We specialize in neuromuscular and rare disease clinical trials. The science is fascinating, but there are a lot more complexities than in other types of clinical trials. Many neuromuscular and other rare diseases have genetic causes, which makes everything even more complicated. It’s important to design your clinical trial protocols to minimize… Read more »

Early Bird Registration for the MDA Conference Closes Soon

December 5, 2018 Even though it’s winter here in the US, spring is just around the corner. In April, clinical providers and researchers will meet for the first combined MDA Clinical and Research Conference in Orlando, Florida. This five day conference is your opportunity to learn from the key opinion leaders caring for children and… Read more »

Frequently Asked Questions: How do You Work with Clients?

November 14, 2018 TRiNDS is a specialized neuromuscular contract research organization offering expert level support for clinical trials, post marketing studies, and academic research. Our clients are biopharmaceutical companies working to develop new treatments for neuromuscular disorders around the world. Our approach is to work in partnership with our clients to meet project goals without… Read more »

New Supplements: Duchenne Muscular Dystrophy Care Guidelines

November 9, 2018 The October 2018 issue of Pediatrics included a set of critical documents for the good care of children with Duchenne Muscular Dystrophy (DMD). The special supplement included a series of 12 articles outlining best practices for multidisciplinary management of DMD. These articles build on the 3-part Lancet overview articles published in January…. Read more »

Happy Fall from the TRiNDS Team!

October 31, 2018 Last week, TRiNDS staff travelled to beautiful Central Pennsylvania from all over the country for our annual retreat. We spent two days together to review our company progress, update our annual training, and to plan for the future. We did take some time for play – everyone enjoyed a visit at a… Read more »

FDA Invites Public Comment On Adaptive Designs

October 25, 2018 The Food and Drug Administration (FDA) released an updated draft guidance to industry in early October entitled, “Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry.” The draft guidance reviews best practices for trial design, analysis, and reporting of clinical trials using different adaptive design strategies. The public is… Read more »

Newborn Screening Update for Duchenne Muscular Dystrophy

October 18, 2018 The Duchenne muscular dystrophy (DMD) community took two big steps toward newborn screening this month. Newborn screening programs are important because they allow early diagnosis even before symptoms are observed. Newborn screening facilitates early treatment and rapid development of new therapies for infants everywhere. When infants are born in the United States,… Read more »

Success at WMS

October 10, 2018 World Muscle Society was a great success for TRiNDS, CINRG, and TRiNDS’ clients and collaborators. In addition to three days of presentations, researchers presented over 175 posters in a poster session. Poster presentations shared results from all different types of research and clinical trials about all different types of neuromuscular disorders. We… Read more »

Building Your Team: Becker Muscular Dystrophy

October 3, 2018 Next week is Becker Muscular Dystrophy (BMD) Awareness Week, a time for everyone to recognize the families around the world living with BMD. BMD affects 1 in 35,000 males worldwide. People with BMD show symptoms of muscle weakness in the teen years and can often keep walking into adulthood. Even though good… Read more »